Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities
Net loss	$ (17,622)	$ (50,317)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	331	260
Research and development license expense		1,250
Stock-based compensation	1,675	5,329
Non-cash lease expense	300	309
Other	128	194
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(400)	271
Accounts payable	359	2,544
Accrued expenses and other liabilities	(250)	(779)
Deferred revenue	(4,706)
Net cash used in operating activities	(20,185)	(40,939)
Cash flows from investing activities
Purchase of research and development license		(3,000)
Purchase of property, plant and equipment	(3,900)	(8,427)
Net cash used in investing activities	(3,900)	(11,427)
Cash flows from financing activities
Payment of shelf registration costs	(387)	(151)
Proceeds from common stock issuances under ESPP	50	277
Other	(33)	(233)
Net cash provided by financing activities	(370)	(107)
Net decrease in cash, cash equivalents and restricted cash	(24,455)	(52,473)
Cash, cash equivalents and restricted cash at the beginning of the period	90,517	151,740
Cash, cash equivalents and restricted cash at the end of the period	66,062	99,267
Cash and cash equivalents	63,425	96,630
Restricted cash	2,637	2,637
Supplemental disclosure of cash flow information:
Cash paid for interest	1,125	419
Supplemental disclosure of noncash investing and financing activities:
Property, plant and equipment in accounts payable and accrued expenses	$ 112	4,513
Right-of-use assets obtained in exchange for lease liabilities		18,634
Offering costs not yet paid		21
Purchase of research and development license not yet paid		$ 1,250